副腎白質ジストロフィー治療薬の世界市場レポート 2025年

副腎白質ジストロフィー治療薬市場規模は、今後数年で急成長が見込まれます。2029年には10億5,000万米ドルに成長し、CAGRは10.9%となります。予測期間に予測される成長は、希少疾患研究への投資の増加、精密医療の採用拡大、発展途上地域におけるヘルスケア支出の増加、新生児スクリーニングプログラムの強化、希少医薬品開発に対する規制当局の支援などに起因しています。この期間の主な動向としては、AIを活用した創薬、早期診断のための次世代シーケンサー、ナノテクノロジーを活用したドラッグデリバリー、幹細胞遺伝子治療の革新、バイオテクノロジー企業間の提携などが挙げられます。

ヘルスケア支出の増加は、副腎白質ジストロフィー（ALD）治療薬市場の主要促進要因です。ヘルスケア支出は、医療サービス、ヘルスケア製品、関連サービスに割り当てられる総財源を含み、増加傾向にあります。これは、人口の高齢化と慢性疾患の蔓延によるところが大きく、いずれも長期的なケアと継続的な管理が必要です。その結果、ALDを含む希少疾患の専門的治療に対するニーズが高まり、研究開発および患者ケアのコストが上昇しています。メディケア・メディケイド・サービスセンター（CMS）によると、米国の国民医療費は2023年に7.5％増とGDPの伸びを上回り、2023年から2032年までは年率5.6％で成長すると予測されています。ヘルスケア支出の増加に伴い、ALD治療薬などの治療需要も増加し、市場の成長が促進されます。

FDAやEMAなどの規制当局による承認は、ALDのような希少疾患の治療選択肢を拡大する上で極めて重要です。これらの承認は、治療が必要な安全性と有効性の基準を満たしていることを保証し、市場導入を可能にします。特筆すべき例として、スペインを拠点とするバイオテクノロジー企業Minoryx Therapeutics社があります。同社は2023年5月、X連鎖性副腎白質ジストロフィー（X-ALD）および脳性副腎白質ジストロフィー（cALD）の成人男性患者を対象としたレリグリタゾン（MIN-102）の第3相臨床試験を開始するためのFDA承認を取得しました。CALYXとして知られるこの臨床試験は、この薬剤が病気の進行を遅らせたり止めたりする能力を評価するもので、治療の選択肢が限られている患者に希望を与えるものです。この臨床試験が成功すれば、商品化につながる可能性があり、これらの壊滅的な症状に苦しむ患者の緊急の医療ニーズに対応することができます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界副腎白質ジストロフィー治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の副腎白質ジストロフィー治療薬市場：成長率分析
• 世界の副腎白質ジストロフィー治療薬市場の実績：規模と成長, 2019-2024
• 世界の副腎白質ジストロフィー治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界副腎白質ジストロフィー治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の副腎白質ジストロフィー治療薬市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 栄養補助食品
• 抗酸化物質
• コルチコステロイド
• 酵素補充療法
• 世界の副腎白質ジストロフィー治療薬市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小児脳性副腎白質ジストロフィー
• アジソン病
• 副腎脊髄ニューロパチー（AMN）
• 世界の副腎白質ジストロフィー治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• 静脈内
• 世界の副腎白質ジストロフィー治療薬市場患者の年齢層別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小児患者
• 成人患者
• 高齢患者
• 世界の副腎白質ジストロフィー治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• その他の流通チャネル
• 世界の副腎白質ジストロフィー治療薬市場、栄養補助食品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オメガ3脂肪酸
• ビタミン
• アミノ酸
• 鉱物
• 世界の副腎白質ジストロフィー治療薬市場抗酸化物質の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ビタミンE
• コエンザイムQ10
• アルファリポ酸
• グルタチオン
• 世界の副腎白質ジストロフィー治療薬市場コルチコステロイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プレドニゾン
• デキサメタゾン
• ヒドロコルチゾン
• メチルプレドニゾロン
• 世界の副腎白質ジストロフィー治療薬市場酵素補充療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ラロニダーゼ
• イデュルスルファーゼ
• ガルスルファーゼ
• セベリパーゼアルファ

第7章 地域別・国別分析

• 世界の副腎白質ジストロフィー治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の副腎白質ジストロフィー治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 副腎白質ジストロフィー治療薬市場：競合情勢
• 副腎白質ジストロフィー治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Teva Pharmaceuticals USA Inc.
• Dr. Reddy's Laboratories
• Poxel S.A.
• Neuraxpharm
• Mallinckrodt Pharmaceuticals plc
• Nutricia
• Viking Therapeutics Inc.
• MedDay Pharmaceuticals SAS
• Voyager Therapeutics Inc.
• Prevail Therapeutics
• Ashvattha Therapeutics
• Magenta Therapeutics Inc.
• Minoryx Therapeutics S.L.
• SwanBio Therapeutics Inc.
• Autobahn Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 副腎白質ジストロフィー治療薬市場2029：新たな機会を提供する国
• 副腎白質ジストロフィー治療薬市場2029：新たな機会を提供するセグメント
• 副腎白質ジストロフィー治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Adrenoleukodystrophy (ALD) drugs are used to manage symptoms and slow the progression of ALD, a rare genetic disorder that impacts the nervous system and adrenal glands. This condition is caused by mutations in the ABCD1 gene, leading to the buildup of very long-chain fatty acids (VLCFAs) in the brain, adrenal glands, and spinal cord.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary drug categories for treating ALD include dietary supplements, antioxidants, corticosteroids, and enzyme replacement therapy. Dietary supplements are oral products containing essential nutrients such as vitamins, minerals, amino acids, and fatty acids, which support overall health and may help manage conditions such as ALD. These treatments are used for a range of conditions, including childhood cerebral adrenoleukodystrophy (CCALD), Addison's disease, and adrenomyeloneuropathy (AMN), and can be administered via oral, injectable, or intravenous routes. They are suitable for different age groups, including pediatric, adult, and geriatric populations, and are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels.

The adrenoleukodystrophy drugs market research report is one of a series of new reports from The Business Research Company that provides adrenoleukodystrophy drugs market statistics, including adrenoleukodystrophy drugs industry global market size, regional shares, competitors with an adrenoleukodystrophy drugs market share, detailed adrenoleukodystrophy drugs market segments, market trends and opportunities, and any further data you may need to thrive in the adrenoleukodystrophy drugs industry. This adrenoleukodystrophy drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The adrenoleukodystrophy drug market size has grown rapidly in recent years. It will grow from$0.63 billion in 2024 to $0.70 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. The growth observed during the historical period can be attributed to heightened awareness of rare diseases, a rise in orphan drug designations, government funding for rare disease research, the development of personalized medicine, and the expansion of healthcare infrastructure.

The adrenoleukodystrophy drugs market size is expected to see rapid growth in the next few years. It will grow to$1.05 billion in 2029 at a compound annual growth rate (CAGR) of 10.9%. The growth projected for the forecast period can be attributed to increased investment in rare disease research, the growing adoption of precision medicine, rising healthcare expenditure in developing regions, enhanced newborn screening programs, and regulatory support for orphan drug development. Key trends during this period include AI-driven drug discovery, next-generation sequencing for early diagnosis, nanotechnology-based drug delivery, innovations in stem cell gene therapy, and collaborations between biotech companies.

The growth of healthcare expenditure is a key driver of the adrenoleukodystrophy (ALD) drugs market. Healthcare expenditure, which includes the total financial resources allocated to medical services, healthcare products, and related services, is on the rise. This is largely due to an aging population and the growing prevalence of chronic diseases, both of which demand long-term care and continuous management. As a result, there is an increased need for specialized treatments for rare diseases, including ALD, which in turn leads to higher costs for research, development, and patient care. According to the Centers for Medicare and Medicaid Services (CMS), U.S. national health expenditures grew 7.5% in 2023, outpacing GDP growth, and are projected to grow at an annual rate of 5.6% from 2023 to 2032. As healthcare expenditure increases, so does the demand for treatments such as ALD drugs, fostering market growth.

Regulatory approvals from agencies such as the FDA and EMA are crucial for expanding the range of treatment options available for rare diseases such as ALD. These approvals ensure that treatments meet the necessary safety and efficacy standards, enabling their market introduction. A notable example is Minoryx Therapeutics, a Spain-based biotechnology company, which in May 2023 received FDA approval to initiate a Phase 3 clinical trial for leriglitazone (MIN-102) in adult male patients with X-linked adrenoleukodystrophy (X-ALD) and cerebral adrenoleukodystrophy (cALD). This clinical trial, known as CALYX, will assess the drug's ability to slow or halt disease progression, providing hope to patients with limited treatment options. A successful trial could lead to commercialization, addressing an urgent medical need for patients suffering from these devastating conditions.

In November 2022, Minoryx Therapeutics entered into a strategic partnership with Neuraxpharm Group to secure exclusive commercialization rights for leriglitazone in Europe. Neuraxpharm, a Germany-based pharmaceutical company specializing in treatments for central nervous system (CNS) disorders, including rare diseases such as X-ALD, will leverage its expertise in the European market to accelerate the commercialization of leriglitazone. This collaboration aims to improve patient access to this promising treatment and support the continued growth of the ALD drug market.

Major players in the adrenoleukodystrophy drugs market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi S.A., AstraZeneca plc, Novartis AG, Teva Pharmaceuticals USA Inc., Dr. Reddy's Laboratories, Poxel S.A., Neuraxpharm, Mallinckrodt Pharmaceuticals plc, Nutricia, Viking Therapeutics Inc., MedDay Pharmaceuticals SAS, Voyager Therapeutics Inc., Prevail Therapeutics, Ashvattha Therapeutics, Magenta Therapeutics Inc., Minoryx Therapeutics S.L., SwanBio Therapeutics Inc., Autobahn Therapeutics Inc., bluebird bio Inc., SOM Biotech, and NeuroVia.

North America was the largest region in the adrenoleukodystrophy drugs market in 2024. The regions covered in adrenoleukodystrophy drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the adrenoleukodystrophy drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The adrenoleukodystrophy drugs market consists of sales of products including corticosteroids, Lorenzo's oil, hydrocortisone tablets, prednisone tablets, and adrenocortical hormone replacement therapy products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Adrenoleukodystrophy Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on adrenoleukodystrophy drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for adrenoleukodystrophy drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The adrenoleukodystrophy drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Dietary Supplements; Antioxidants; Corticosteroids; Enzyme Replacement Therapy
• 2) By Indication: Childhood Cerebral Adrenoleukodystrophy; Addison's Disease; Adrenomyeloneuropathy (AMN)
• 3) By Route Of Administration: Oral; Injectable; Intravenous
• 4) By Patient Age Group: Pediatric Patients; Adult Patients; Geriatric Patients
• 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Dietary Supplements: Omega-3 Fatty Acids; Vitamins; Amino Acids; Minerals
• 2) By Antioxidants: Vitamin E; Coenzyme Q10; Alpha-Lipoic Acid; Glutathione
• 3) By Corticosteroids: Prednisone; Dexamethasone; Hydrocortisone; Methylprednisolone
• 4) By Enzyme Replacement Therapy: Laronidase; Idursulfase; Galsulfase; Sebelipase Alfa
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Sanofi S.A.; AstraZeneca plc; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Adrenoleukodystrophy Drugs Market Characteristics

3. Adrenoleukodystrophy Drugs Market Trends And Strategies

4. Adrenoleukodystrophy Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Adrenoleukodystrophy Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Adrenoleukodystrophy Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Adrenoleukodystrophy Drugs Market Growth Rate Analysis
• 5.4. Global Adrenoleukodystrophy Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Adrenoleukodystrophy Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Adrenoleukodystrophy Drugs Total Addressable Market (TAM)

6. Adrenoleukodystrophy Drugs Market Segmentation

• 6.1. Global Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dietary Supplements
• Antioxidants
• Corticosteroids
• Enzyme Replacement Therapy
• 6.2. Global Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Childhood Cerebral Adrenoleukodystrophy
• Addison's Disease
• Adrenomyeloneuropathy (AMN)
• 6.3. Global Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Intravenous
• 6.4. Global Adrenoleukodystrophy Drugs Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric Patients
• Adult Patients
• Geriatric Patients
• 6.5. Global Adrenoleukodystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
• 6.6. Global Adrenoleukodystrophy Drugs Market, Sub-Segmentation Of Dietary Supplements, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Omega-3 Fatty Acids
• Vitamins
• Amino Acids
• Minerals
• 6.7. Global Adrenoleukodystrophy Drugs Market, Sub-Segmentation Of Antioxidants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vitamin E
• Coenzyme Q10
• Alpha-Lipoic Acid
• Glutathione
• 6.8. Global Adrenoleukodystrophy Drugs Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prednisone
• Dexamethasone
• Hydrocortisone
• Methylprednisolone
• 6.9. Global Adrenoleukodystrophy Drugs Market, Sub-Segmentation Of Enzyme Replacement Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Laronidase
• Idursulfase
• Galsulfase
• Sebelipase Alfa

7. Adrenoleukodystrophy Drugs Market Regional And Country Analysis

• 7.1. Global Adrenoleukodystrophy Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Adrenoleukodystrophy Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Adrenoleukodystrophy Drugs Market

• 8.1. Asia-Pacific Adrenoleukodystrophy Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Adrenoleukodystrophy Drugs Market

• 9.1. China Adrenoleukodystrophy Drugs Market Overview
• 9.2. China Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Adrenoleukodystrophy Drugs Market

• 10.1. India Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Adrenoleukodystrophy Drugs Market

• 11.1. Japan Adrenoleukodystrophy Drugs Market Overview
• 11.2. Japan Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Adrenoleukodystrophy Drugs Market

• 12.1. Australia Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Adrenoleukodystrophy Drugs Market

• 13.1. Indonesia Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Adrenoleukodystrophy Drugs Market

• 14.1. South Korea Adrenoleukodystrophy Drugs Market Overview
• 14.2. South Korea Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Adrenoleukodystrophy Drugs Market

• 15.1. Western Europe Adrenoleukodystrophy Drugs Market Overview
• 15.2. Western Europe Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Adrenoleukodystrophy Drugs Market

• 16.1. UK Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Adrenoleukodystrophy Drugs Market

• 17.1. Germany Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Adrenoleukodystrophy Drugs Market

• 18.1. France Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Adrenoleukodystrophy Drugs Market

• 19.1. Italy Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Adrenoleukodystrophy Drugs Market

• 20.1. Spain Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Adrenoleukodystrophy Drugs Market

• 21.1. Eastern Europe Adrenoleukodystrophy Drugs Market Overview
• 21.2. Eastern Europe Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Adrenoleukodystrophy Drugs Market

• 22.1. Russia Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Adrenoleukodystrophy Drugs Market

• 23.1. North America Adrenoleukodystrophy Drugs Market Overview
• 23.2. North America Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Adrenoleukodystrophy Drugs Market

• 24.1. USA Adrenoleukodystrophy Drugs Market Overview
• 24.2. USA Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Adrenoleukodystrophy Drugs Market

• 25.1. Canada Adrenoleukodystrophy Drugs Market Overview
• 25.2. Canada Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Adrenoleukodystrophy Drugs Market

• 26.1. South America Adrenoleukodystrophy Drugs Market Overview
• 26.2. South America Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Adrenoleukodystrophy Drugs Market

• 27.1. Brazil Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Adrenoleukodystrophy Drugs Market

• 28.1. Middle East Adrenoleukodystrophy Drugs Market Overview
• 28.2. Middle East Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Adrenoleukodystrophy Drugs Market

• 29.1. Africa Adrenoleukodystrophy Drugs Market Overview
• 29.2. Africa Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Adrenoleukodystrophy Drugs Market Competitive Landscape And Company Profiles

• 30.1. Adrenoleukodystrophy Drugs Market Competitive Landscape
• 30.2. Adrenoleukodystrophy Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Adrenoleukodystrophy Drugs Market Other Major And Innovative Companies

• 31.1. Teva Pharmaceuticals USA Inc.
• 31.2. Dr. Reddy's Laboratories
• 31.3. Poxel S.A.
• 31.4. Neuraxpharm
• 31.5. Mallinckrodt Pharmaceuticals plc
• 31.6. Nutricia
• 31.7. Viking Therapeutics Inc.
• 31.8. MedDay Pharmaceuticals SAS
• 31.9. Voyager Therapeutics Inc.
• 31.10. Prevail Therapeutics
• 31.11. Ashvattha Therapeutics
• 31.12. Magenta Therapeutics Inc.
• 31.13. Minoryx Therapeutics S.L.
• 31.14. SwanBio Therapeutics Inc.
• 31.15. Autobahn Therapeutics Inc.

32. Global Adrenoleukodystrophy Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Adrenoleukodystrophy Drugs Market

34. Recent Developments In The Adrenoleukodystrophy Drugs Market

35. Adrenoleukodystrophy Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Adrenoleukodystrophy Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Adrenoleukodystrophy Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Adrenoleukodystrophy Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34745_Adrenoleukodystrophy Drugs_GMR_2025